Health Care·Pharmaceuticals·$49.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.38 | N/A | +2.76% |
management commentary, guidance changes, and full analysis available with Pro.
| +2.76% |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's market position. They emphasized the importance of continued product development and customer engagement.
Management highlighted strong demand for animal health products.
They noted ongoing investments in innovation to drive future growth.
Zoetis reported a better-than-expected EPS for the first quarter, which contributed to a positive stock reaction, with shares rising by 5.51%. The strong demand for their products and focus on innovation were key factors driving investor confidence. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BANCO BILBAO VIZCAYA ADR
Apr 29, 2024